SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artculo

DIESTRO TEJEDA, M. D.; SERRANO VELASCO, M.  y  GOMEZ-PASTRANA NIETO, F.. Cáncer de cuello uterino: Estado actual de las vacunas frente al virus del papiloma humano (VPH). Oncología (Barc.) [online]. 2007, vol.30, n.2, pp.14-31. ISSN 0378-4835.

    1. Bosch FX, Lorincz A, Muñoz M, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265. [ Links ]

    2. Lowndes CM. Vaccines for cervical cancer. Epidemiol Infect 2006; 134 (1): 1-12. [ Links ]

    3. Ferlay J, Bray F, Pisan P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC, 2004;147. [ Links ]

    4. Bosch FX, Diaz M, De Sanjosé S, et al. Epidemiología de las infecciones por el virus del papiloma humano (HPV): riesgo de carcinoma cérvico-uterino y otros tumores ano-genitales. Nuevas opciones preventivas. En: De Sanjosé S, García AM. 4 Monografía de la Sociedad Española de Epidemiología. Virus del Papiloma Humano y Cáncer: epidemiología y prevención. Madrid: EMISA, 2006: 31-50. [ Links ]

    5. Miñarro R, Black RJ, Martínez C, Navarro C, Garau I, Izarzugaza I, et al. Cancer Incidence and Mortality in Spain- Patterns and Trends. IARC Technical Report n 36. Lyon: IARC, 2000; 27. [ Links ]

    6. Parkin DM, Whelan SL, Ferlay J. Cancer Incidence in Five Continents. Vol III. IARC Scientific Publication N 155. Lyon: IARC, 2002; 27. [ Links ]

    7. Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005; 14: 677-86 [ Links ]

    8. De Sanjosé S. La investigación sobre la infección por virus del papiloma humano (VPH) y el cáncer de cuello uterino en España. En: De Sanjosé S, García AM. 4 Monografía de la Sociedad Española de Epidemiología. Virus del Papiloma Humano y Cáncer: epidemiología y prevención. Madrid: EMISA, 2006: 141-146. [ Links ]

    9. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118 (12): 3030-3044. [ Links ]

    10. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997. 102: 3-8. [ Links ]

    11. Syrjänen y Syrjánen. Papillomavirus infections in human pathology. Chichester: Wiley & Sons, 2000; 117-141. [ Links ]

    12. De San José S, Díaz M, Castellsagué X, Clifford G, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical HPV DNA in 169-341 women from general population. A meta-analysis of the international literature. 2006 (enviado para publicación). [ Links ]

    13. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87: 324-333. [ Links ]

    14. Ferreccio C, Prado RB, Luzoro AV, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago,Chile. Cancer Epidemiol Biomarkers Prev 2004; 13: 2271-2276. [ Links ]

    15. Thomas JO, Herrero R, Omigbodun AA, et al. Prevalence of papillomavirus infection in women in Ibadan, Nigheria: a population-based study. Br J Cancer 2004; 90: 638-645. [ Links ]

    16. Forslund O, Antonsson A, Edlund K, et al. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002; 66: 535-541. [ Links ]

    17. De San José S, Almirall R, Lloveras B, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003; 30: 788-793. [ Links ]

    18. Del Almo J, González C, Losana J. La infección por virus del papiloma humano en poblaciones a alto riesgo de cáncer de cuello uterino en España. En: De Sanjosé S, García AM. 4 Monografía de la Sociedad Española de Epidemiología. Virus del Papiloma Humano y Cáncer: epidemiología y prevención. Madrid: EMISA, 2006: 71-88. [ Links ]

    19. Múgica-Van Herckenrode C, Malcom AD, Coleman DV. Prevalence of human papillomavirus infection in basque Country women using slot-blot hybridization: a survey of women at low risk of developing cervical cancer. Int J Cancer 1992; 51 (4): 581-586. [ Links ]

    20. Font R, Pérez M, Coll C, et al. Utilización de modelos longitudinales para estimar el tiempo de regresión/progresión de la infeccion por VPH en una cohorte de mujeres atendidas en centros de planificación familiar en Barcelona, España. Gac Sanit 2004; 18(3): 148. [ Links ]

    21. Puig F, Echavarren V, Yago T, et al. Prevalence of HPV in a random simple o fan urban population in the city of Zaragoza (Spain). Prog Obstet Ginecol 2005; 48(4): 172-178 [ Links ]

    22. González C, Ortiz M, Canals J, et al. Higher prevalence of HPV infection in migrant women from Latinoamerica in Spain. Sex Transm Infect 2006; 82: 260-262. [ Links ]

    23. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831-1836. [ Links ]

    24. Walboomers JM, Jacobs MV, Manos MM, et al. Human papilomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-19. [ Links ]

    25. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14(5): 1157-1164. [ Links ]

    26. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91: 506-511. [ Links ]

    27. Castellsague X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives and tobacco smoking. J Natl Cancer Inst Monogr 2003; (31): 20-28. [ Links ]

    28. Castellsague X, Díaz M, De San José S, et al. The worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors:implications for screening and prevention. J Natl Cancer Inst 2006; 98 (5): 303-315. [ Links ]

    29. IARC Technical reports N3. Tabacco smoke and involuntary smoking. Lyon: IARC Press, 2004. [ Links ]

    30. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk of development of cervical squamous cell carcinoma. J Am Med Assoc 2001; 285:47-51. [ Links ]

    31. Smith JS, Muñoz N, HerreroR, et al. Evidence for Chlamydia Trachomatis as a human papillomavirus cofactor in etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 2002; 185: 324-331. [ Links ]

    32. Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk for cervical cancer: a longitudinal nested case-control study in the Nordic countries. Am J Epidemiol 2002; 156: 687-692. [ Links ]

    33. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388-2394. [ Links ]

    34. Manhart LE, Koutsky LA. Do condoms prevent HPV infection, external genital warts or cervical neoplasia? A meta-analisys. Sex Transm Dis 2002; 29: 725. [ Links ]

    35. Castellsague X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346 (15): 1105-1112. [ Links ]

    36. Trimble CL, Hildesheim A, Brinton LA, Shah KV, Kurman RJ. Hetereogenus etiology of squamous carcinoma of the vulva. Obstet Gynecol 1996; 87: 59-64. [ Links ]

    37. Ishi K, Suzuki F, Saito A, Kubota T. Infect Prevalence of HPV, Chlamydia Trachomatis and Neisseria gonorrhoeae in commercial sex workwers in Japan. Infect Dis Obstet Gynecol 2000; 8: 235-239. [ Links ]

    38. Juarez LA, Wheeler CM, Uribe –Salas FJ, et al. HPV: a hihgly prevalent sexualy transmited disease agent among female sex workers from Mejico City. Sex Transm Dis 2001; 28(3): 125-130. [ Links ]

    39. Touzé A, De San José S, Coursaget P, et al. Prevalence of antihuman papillomavirus type 16, 18, 31 and 58 virus-like particles in women in the general population in prostitutes. J Clin Microb 2001; 39(12): 4344-4348. [ Links ]

    40. De San José S, Valls I, Paz M, et al. HPV and human immunodeficiency virus infections as risk factors for cervix cancer in women prisioners. Med Clin (Barc) 2000; 115: 81-84. [ Links ]

    41. Hemminki K, Dong C, Vaittinen P. Familiar risks in cervical cancer: is there a hereditary component? Int G Cancer 1999; 82: 775-781. [ Links ]

    42. Ahdieh L, Klein RS ,Burk R, et al. Prevalence, incidence and type-specific persistence of HPV in HIV-positive and HIV-negative women. J Infect Dis 2001; 184: 682-690. [ Links ]

    43. De Williers EM, Fauquet C, Broker TR, et al. Classification of papilomaviruses. Virology 2004; 324: 17-27. [ Links ]

    44. Stanley MA. HPV vaccines: prospects for eradicating cervical cancer. J Fam Plann Reprod Health Care 2004; 30(4): 213-215. [ Links ]

    45. Ortiz M, Torres M, García A. Determinación del virus del papiloma humano (VPH): aspectos técnicos. En: De Sanjosé S, García AM. 4 Monografía de la Sociedad Española de Epidemiología. Virus del Papiloma Humano y Cáncer: epidemiología y prevención. Madrid: EMISA, 2006: 89-106. [ Links ]

    46. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papilomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796-802. [ Links ]

    47. Stanley MA. Human papillomavirus vaccines. Rev Med Virol 2006; 16: 139-149. [ Links ]

    48. Muñoz N, Bosch FX, De San José S, et al. International agency for research on cancer multicenter cervical cancer study group. Epidemiologic classification of HPV types associated with cervical cancer. N Engl J Med 2003; 348: 518-527. [ Links ]

    49. Stanley MA. Inmune responses to HPV. Vaccine 2006; 1: 16-22. [ Links ]

    50. Stanley MA. Virus-keratinocyte interactions in the infectious cycle. En: Stern PL, Stanley MA. HPV and cervical cancer. Oxford: Oxford University Press, 1994; 116-131. [ Links ]

    51. Oriel JD. Natural History of genital warts. BR J Vener Dis 1971; 47: 1-13. [ Links ]

    52. Frazer IH, Cox JT, Mayeaux EJ, et al. Advances in Prevention of Cevical Cancer and Other Human Papillomavirus-Related Diseases. Pediatrics Infect Dis J 2006; 25: S65-S81. [ Links ]

    53. Chow LT, Broker TR. Mechanisms and regulation of papillomavirus DNA replication. En: Saveria Campo MS , editor. Papillomavirus research from natural history to vaccines and beyond. Norwich: Caister Academic Press, 2005; 53-71. [ Links ]

    54. Padilla-Paz LA. Human Papillomavirus Vaccine: History, Inmunology, Current Status, and Future Prospects. Clin Obstet and Gynecol 2005; 48 (1): 226-240. [ Links ]

    55. Elfgren K, Kalantari M, Moberger B, Hahmar B, Dillner J. A population-based five-year follow-up study of cervical HPV infection. Am J Obstet Gynecol 2000; 183: 561-567. [ Links ]

    56. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 (1): S16-S24. [ Links ]

    57. Khan MJ. The elevated 10-year risk of cervical precancer and cancer in women with HPV type 16 or 18 and the possible utility of type specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079. [ Links ]

    58. Castle PE, Solomon D, Schiffman M, Wheeler CM. HPV type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild citologyc abnormalities. J Natl Cancer Inst 2005; 97(14): 1066-1071. [ Links ]

    59. Kjaer SK, Van der Brule AJ, Paull G, et al. Type specific persistente of high risk HPV as indicador of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 572. [ Links ]

    60. IARC Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J (Clin Res Ed) 1986; 293: 659-664. [ Links ]

    61. Martin-Hirsch PL, Koliopoulos G, Paraskevaidis E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. Eur J Gynaecol Oncol 2002; 23: 363-365. [ Links ]

    62. Grupo de cáncer de cuello uterino. Gonzalez Merlo J, Abad L, Balagueró L, et al. En: Documentos de consenso de la SEGO. Madrid: Editorial Meditext, 1997: 115-130. [ Links ]

    63. Krane JF, Granter SR, Trask CE, Hogan CL, Lee KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001; 93 (1): 8-15. [ Links ]

    64. De San José S, Alejo M, Combalia N, et al. Historia del cribado en mujeres con cáncer infiltrante de cuello uterino. Gaceta Sanitaria 2006; 20 (2): 166-170. [ Links ]

    65. Gálvez IM, González J, Lubián M. Cribado de cáncer de cérvix. A quién y cuéndo. Atención primaria 1998; 21: 234-239. [ Links ]

    66. Puig-Tintoré LM, De San José S, Méndez C, et al. Prevención secundaria: situación actual del cribado del cáncer de cuello uterino en España. En: De Sanjosé S, García AM. 4 Monografía de la Sociedad Española de Epidemiología. Virus del Papiloma Humano y Cáncer: epidemiología y prevención. Madrid: EMISA, 2006: 131-140. [ Links ]

    67. Bolick DR, Hellman DJ. Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system. Acta Cytologica 1998; 42 (1): 209-213. [ Links ]

    68. HPV Today (versión española) N 7. HPV en 100 diapositivas. Madrid: Bypass Comunicación en salud, S. L. 2005; Octubre: 13. (http://www.hpvtoday.com). [ Links ]

    69. Cox, Salomón, et al. ALTS followup. Am J Obstet Gynecol 2003; 1406-1410. [ Links ]

    70. Ponce J. Cribado del cáncer de cuello uterino. En: Cabero Ll, Iglesias X, Balagueró Ll, Xercavins J. XII Curso intensivo de formación continuada. Ginecología Oncológica. Madrid: Ediciones Ergón, S. A. 2005; 35-42. [ Links ]

    71. Puig-Tintoré LM, Cortés J, Castellsague X, et al. Prevención del cáncer de cuello uterino ante la vacunación frente al virus del papiloma humano. Prog Obstet Ginecol 2006; 49 (2): 5-62. [ Links ]

    72. Bosch FX, de Sanjosé S. Epidemiología de las infecciones por el virus del papiloma humano (VPH) y sus asociadas. En: Cabero Ll, Iglesias X, Balagueró Ll, Xercavins J. XII Curso intensivo de formación continuada. Ginecología Oncológica. Madrid: Ediciones Ergón, S. A. 2005; 7-14. [ Links ]

    73. Ponce J, Vilata JJ. Infección por el virus del papiloma humano (VPH). Consejo multidisciplinar del Foro VPH. Prog Obstet Ginecol 2001; 44: 289-323. [ Links ]

    74. Castellsagué X, Albero G, Martí D, et al. Prevención primaria: vacunas frente al virus del papiloma humano (VPH) para la prevención del cáncer de cuello uterino. En: De Sanjosé S, García AM. 4 Monografía de la Sociedad Española de Epidemiología. Virus del Papiloma Humano y Cáncer: epidemiología y prevención. Madrid: EMISA, 2006: 107-130. [ Links ]

    75. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185 (1): 251-257. [ Links ]

    76. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 1996; 7 (6): 373-382. [ Links ]

    77. Xercavins J, Gil A, Centeno C. Virus y cáncer genital. En: Cabero Ll, Iglesias X, Balagueró Ll, Xercavins J. IX Curso intensivo de formación continuada. Ginecología Oncológica. Madrid: Ediciones Ergón S. A. 2002; 9-16. [ Links ]

    78. Billich A. HPV vaccine MedImmune/GlaxoSmithKline. Current Opinión in Investigational Drugs 2003; 4 (2): 210-213. [ Links ]

    79. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651. [ Links ]

    80. Lehtinen M, Paavonen J. Vaccination against human papilomaviruses shows great promise. Lancet 2004; 364: 1731-1732. [ Links ]

    81. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004; 2: 343-347. [ Links ]

    82. Villa LL, Costa RL, Petta CA, et al Prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278. [ Links ]

    83. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116 (5): 1167-1173. [ Links ]

    84. Kirnbauer R, Chandrachud LM, O´Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219 (1): 37-44. [ Links ]

    85. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular inmunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937-5949. [ Links ]

    86. Taff J. Overview: Vaccines against human papilloma viruses. Current Opinion in Investigacional Drugs 2006; 7 (8): 699-701. [ Links ]

    87. Shaw AR. Human papillomavirus vaccines in development: If they´re successful in clinical trials, how will they be implemented? Gynecol Oncol 2005; 99: S246-S248. [ Links ]

    88. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004; 364 (9447): 1757-1765. [ Links ]

    89. Steinbrook R. The Potential of Human Papillomavirus Vaccines. N Engl J Med 2006; (354): 1109-1112. [ Links ]

    90. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255. [ Links ]

    91. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-11923. [ Links ]

    92. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol 2002; 76 (15): 7832-7842. [ Links ]

    93. Nardelli-Haefliger D. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95: 1128-1137. [ Links ]

    94. Fife KH, Wheeler CM, Koutsky LA, et al. Dosseranging studies of the safety aand immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle vaccines in young healthy women. Vaccine 2004; 22: 2943-2952. [ Links ]

    95. Orozco JJ, Carter JJ, Koutsky LA, Galloway DA. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 11 capsomers. J Virol 2005; 79: 9503-9514. [ Links ]

    96. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003; 183: 561-567. [ Links ]

    97. Ohlschlager P, Osen W, Dell K, et al. Human papillomavirus type 16 L1 capsomeres induce L1 specific cytotoxic CTL lymphocytes and tumour regression in C57BL/6mice. J Virol 2003; 77: 4635-4645. [ Links ]

    98. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13: 110-116. [ Links ]

    99. Dubin G, Colau B, Zahaf T, Quint W, Martin M, Jenkins D. Cross-Protection against persistent HPV infection, abnormal cytology and CIN associated with HPV-16 and 18 realted HPV types by a HPV 16/18 L1 virus-like particle vaccine. Abstract 22 International Papillomavirus Conference and Clinical Workshop, 30 abril-6 de mayo 2005- Vancouver, Canadá. [ Links ]

    100. Muñoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen?. The international perspective. Int J Cancer 2004; 111: 278-285. [ Links ]

    101. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73. [ Links ]

    102. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631-639. [ Links ]

    103. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006; 107 (1): 18-27. [ Links ]

    104. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 2006; 24 (27-28): 5571-5583. [ Links ]

    105. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48. [ Links ]

    106. Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177: 1710-1714. [ Links ]

    107. Paavonen J, Halttunen M, Hansson BG, Nieminen P, Rostila T, Lehtinen M. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies. J Clin Virol 2000; 19: 25-30. [ Links ]

    108. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005; 353: 2101-2104. [ Links ]

    109. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-226. [ Links ]

    110. Family Health International. Reproductive health of young adults. 2003. Avalaible at: http://www.fhi.org/training/en/modules/ADOL/s1pg15.htm. [ Links ]

    111. Merck & Co Inc: Merck & Co´s Gardasil cervical cancer vaccine available in US. Press Release 2006: June 09. [ Links ]

    112. Monsonego J. Cervical cancer prevention: the impact of HPV vaccination. Gynecologie, Obstetrique & Fertilite 2006; 34 (3): 189-201. [ Links ]

    113. Collins Y, Einstein MH, Gostout BS, et al Cervival cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecologic Oncology 2006; 102 (3): 552-562. [ Links ]

    114. Pichichero ME. Prevention of cervical cancer through vaccination of adolescents. Clinical Pediatrics 2006; 45 (5): 393-398. [ Links ]

    115. Holcomb B, Bailey JM, Crawford K, Ruffin MT. Adults´ knowledge and behaviors related to human papillomavirus infection. J Amn Board Fam Pract 2004; 17: 26-31. [ Links ]

    116. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 2004; 58: 1405-1413. [ Links ]

    117. De Melo-Martin I. The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection. Oncologist 2006; 11 (4): 393-396. [ Links ]

    118. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer is a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004: 109: 418-424. [ Links ]

    119. Denny L. The prevention of cervical cancer in developing countries. Intern Journal Obstetrics & Gynaecology 2005; 112 (9): 1204-1212. [ Links ]

    120. Yuan H, Estes PA, Chen Y, et al. Inmunization with a apentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001; 75: 7848-7853. [ Links ]

    121. Balmelli C, Roden R, Potts A, Schiller J, Grandi P, Nardelli-Haefliger D. Nasal inmunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998; 72 (10): 8220-8229. [ Links ]

    122. Sasagawa T, Tani M, Basha W, et al. A human papillomavirus type 16 vaccine by oral delivery on L1 protein. Virus Research 2005; 110: 81-90. [ Links ]

    123. Maclean J, Rybicki E, Williamson A. Vaccination strategies for the prevention of cervical cancer. Expert Rev Anticancer Ther 2005; 5 (1): 97-107. [ Links ]

    124. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in preinvasive and invasive cancer. Vaccine 2001; 19: 2549-2556. [ Links ]

    125. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-353. [ Links ]

    126. Kulasingam SL, Myers ER. Potencial health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-789. [ Links ]

    127. Pagliusi SR, Aguado M. Efficacy and other milestones for human papillomavirus vaccines introduction. Vaccine 2004; 23: 569-578. [ Links ]

    128. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003; 362: 1871-1876. [ Links ]

    129. Tomson TT, Roden RBS, Wu T-C. Human papillomavirus vaccines for the prevention and treatment of human cervical cancer. Curr Opin Investig Drugs 2004; 5 (12): 1247-1261. [ Links ]

    130. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 2005; 10 (7): 528-538. [ Links ]

    131. Davidson EJ, Boswell CM, Sehr P, et al. Inmunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032-6041. [ Links ]

    132. Jansen KU. Vaccines against cervical cancer. Expert Opin Biol Ther 2004; 4 (11): 1803-1809. [ Links ]

    133. Da Silva DM, Kast WM. Vaccination against cervical cancer: hopes and realities. Am J Cancer. 2005; 4 (4): 207-219. [ Links ]

    134. Berzosky JA, Jeffrey DA, Janik J, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004; 114 (4): 450-462. [ Links ]

    135. Brinkman JA, Caffrey AS, Muderspach LI, Roman LD, Kast WM. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol 2005; 26 (2): 129-142. [ Links ]

    136. Corona CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2 and CIN 3) associated with infection by oncogenic human papillomavirus. Human Gene Ther 2004; 15 (5): 421-431. [ Links ]

    137. Stern PL. Recent developments in human papillomavirus vaccine. Expert Opin Investig Drugs 2004; 13 (8): 959-971. [ Links ]